More Patent Reform Legislative Hearings
- Emery Simon Counsel, The Small Business Software Alliance (BSA)
- Philip S. Johnson Chief Patent Counsel, Johnson & Johnson on behalf of the
Pharmaceutical Research and Manufacturers of America (PhRMA)
- Robert B. Chess Chairman, Nektar Therapeutics on behalf of the Biotechnology Industry Organziation (BIO) and
- John R. Thomas Professor, Georgetown University Law Center
The draft amendment, which is a substitute bill, is clearly one supported by both PhRMA and BIO. It’s highly likely that BSA strongly opposes the draft amendment – it completely eliminates two of the provisions backed by the group (the injunctive relief provision and the “second window” for post-grant review proceedings in the Patent and Trademark Office).
The hearing should be quite interesting. If only you could be a fly on the wall. Oh, wait, you can — watch the webcast here.
And don't forget to also check out Buchanan's latest thoughts on "patent trolls":
Here’s the bottom line – the term is impossible to define without circumscribing
the property right provided by patents. Any attempt to do so creates a policy
nightmare. Continuing to do so stands to derail the real patent reform movement
that should be focused on patent quality.
If a patent is valid and enforceable, it should not matter who owns it. Period.
I think Dean Kamen stated it best after being introduced at the recent Conference on Patent Reform in DC, “Hello. I’m Dean Kamen. I’m a troll.”